Navigation Links
ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
Date:6/2/2009

ClearTrial will lead panel of adaptive trial experts offering practical guidelines for designing and implementing adaptive studies. As adaptive clinical trials become more prevalent, their operational planning challenges often remain overlooked in the clinical development process. Adaptive trials place a greater burden on the initial trial design, ranging from understanding the potential for changes in resource allocations to the need for more accurate simulations.

Chicago, IL (PRWEB) June 2, 2009 -- ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that Molly Blake-Michaels, Director, Clinical Services, will chair a panel of adaptive trial design experts on the topic of "Effective Operational Planning for Adaptive Clinical Trials" at the DIA 45th Annual Meeting. Held at the San Diego Convention Center, June 21-25, 2009, the meeting will bring together the biggest names from industry, regulatory, and academia to instruct on the issues affecting global drug discovery and development.

As adaptive clinical trials become more prevalent, their operational planning challenges often remain overlooked in the clinical development process. Adaptive trials place a far greater burden on the initial trial design, ranging from understanding the potential for changes in resource allocations and demands in areas such as biostatistics and drug supply, to the need for more accurate simulations of differing trial scenarios and their operational elements.

During this session, the panel of experts will examine these challenges and provide practical design and implementation guidelines for adaptive trials, including:

*Operational best practices for more successful adaptive trials
*Improving budgeting and forecasting accuracy
*IT considerations, including interactive voice response, electronic data capture, and upfront database design
*Impact of adaptive trial designs on drug supply

Blake-Michaels brings more than 20 years of clinical operations experience to the DIA session, with extensive experience in the strategic planning and execution of clinical development programs across a wide variety of therapeutic areas. Before joining ClearTrial, she worked for pharmaceutical companies such as Abbott Labs, Fujisawa, TAP, Hospira, and Ovation, as well as one of the largest clinical research organizations. Blake-Michaels has authored over 50 clinical study protocols that included adaptive studies, several investigator brochures and FDA briefing books, and multiple NDA summary documents. As an independent clinical research consultant, she prepared clients for FDA Advisory Committee meetings and post-acquisition portfolio reviews, and planned and managed numerous studies, including a REMS-required patient registry.

About ClearTrial®
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2487144.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer
2. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
3. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
4. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
5. Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
6. Vasogen Appoints Dr. Eldon Smith Chairman
7. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
8. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
9. Joseph Loscalzo, M.D., PhD. to Join N30 Pharma Board and Chair Scientific Advisory Board
10. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
11. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology:
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
Breaking Biology News(10 mins):